Each program draws on the same fully characterized iPSC bank. Cartilage, cardiac, and neurodegeneration are the first three indications. The platform was built to support more.
The product is engineered HLA-matched cells delivered through a single intra-articular injection. Because the cells come from the matched bank, the patient does not need immunosuppression. The therapy is therefore safe for the chronic-disease population that current cartilage repair cannot reach.
Long QT syndrome is a life-threatening cardiac arrhythmia that begins in the genes for ion-channel proteins. iPSC-derived cardiomyocytes from the matched bank give us a disease model we can edit and a therapy candidate we can manufacture.
The same iPSC bank that supplies G3N-004 supplies the cardiomyocytes for this program. We are working through the disease-modeling stage in 2026 and 2027, with the goal of an IND submission in 2029 and a Phase I start the following year. Orphan designation work is in parallel.
This program is a working illustration of why a single matched cell bank is valuable. The same bank lets us build a cartilage product and a cardiac product without rebuilding the manufacturing every time.
G3N-012 targets the protein-aggregation pathways that drive neurodegeneration, with an early focus on alpha-synuclein in Parkinson's disease. The bank includes more than 230 Parkinson's patient samples, which lets us build patient-specific iPSC lines and test therapy candidates against them.
The same differentiation work that produces neurons from the bank also gives us a renewable supply of human neuronal tissue for drug screens. Both uses, modeling and therapy, run off the same characterized iPSC source.
We hold a granted patent on iPSC-derived diagnostics for Parkinson's disease. That patent anchors our position in the neurodegenerative program and gives us freedom to operate in the indication.
The program runs on the same HLA-matched cell bank and the same differentiation methods as our lead programs. Neurodegeneration is one of the largest unmet needs in medicine. The platform extends naturally into it.
If you are working on a related indication, or you want to license a specific cell type from the bank, or you want to discuss co-development, the door is open.